Drugs that contain Inotersen Sodium

1. Drug name - TEGSEDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(5 months from now)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(10 months from now)

US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(2 years from now)

US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

CN103038345B AKCEA THERAPS Transthyretin Modulates The Expression Of
Apr, 2031

(8 years from now)

CN103038345A AKCEA THERAPS Adjusting Rotating Transthyretin Protein Expression.
Apr, 2031

(8 years from now)

IN330263B AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

IN201209956P4 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP604409B1 AKCEA THERAPS Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP604409A4 AKCEA THERAPS Compositions And Methods For Detecting And Modulating Rna Activity And Gene Expression.
Jan, 2011

(11 years ago)

EP604409A1 AKCEA THERAPS Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP517859A1 AKCEA THERAPS Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859A4 AKCEA THERAPS Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859B1 AKCEA THERAPS Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP529008A4 AKCEA THERAPS Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008A1 AKCEA THERAPS Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008B1 AKCEA THERAPS Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP544757A4 AKCEA THERAPS Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757A1 AKCEA THERAPS Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757B1 AKCEA THERAPS Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544716A4 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716A1 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716B1 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544792A1 AKCEA THERAPS Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP544792B1 AKCEA THERAPS Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP549615B1 AKCEA THERAPS Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP549615A1 AKCEA THERAPS Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544792A4 AKCEA THERAPS Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP549615A4 AKCEA THERAPS Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544713A4 AKCEA THERAPS Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713A1 AKCEA THERAPS Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713B1 AKCEA THERAPS Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP586520A1 AKCEA THERAPS Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586520A4 AKCEA THERAPS Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586520B1 AKCEA THERAPS Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586570B1 AKCEA THERAPS Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586570A1 AKCEA THERAPS Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586570A4 AKCEA THERAPS Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP590082A1 AKCEA THERAPS Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP590082A4 AKCEA THERAPS Antisense Oligonucleotide Inhibition Of The Ras Gene.
Jun, 2012

(10 years ago)

EP590082B1 AKCEA THERAPS Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP655088A1 AKCEA THERAPS Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP655088A4 AKCEA THERAPS Oligonucleotides Having Chiral Phosphorus Linkages.
Oct, 2012

(9 years ago)

EP655088B1 AKCEA THERAPS Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP724447A4 AKCEA THERAPS Derivatized Oligonucleotides Having Improved Uptake And Other Properties
Oct, 2012

(9 years ago)

EP724447B1 AKCEA THERAPS Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP724447A1 AKCEA THERAPS Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP618925A1 AKCEA THERAPS Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987B1 AKCEA THERAPS Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A3 AKCEA THERAPS Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A2 AKCEA THERAPS Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979A2 AKCEA THERAPS Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979B1 AKCEA THERAPS Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979A3 AKCEA THERAPS Gapped 2' Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP618925A4 AKCEA THERAPS Gapped 2' Modified Oligonucleotides.
Dec, 2012

(9 years ago)

EP618925B2 AKCEA THERAPS Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP618925B1 AKCEA THERAPS Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP672180B1 AKCEA THERAPS Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP672180A4 AKCEA THERAPS Oligonucleotide Modulation Of Protein Kinase C.
Feb, 2013

(9 years ago)

EP672180A1 AKCEA THERAPS Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP649429B1 AKCEA THERAPS Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429A1 AKCEA THERAPS Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429A4 AKCEA THERAPS Heteroatomic Oligonucleoside Linkages.
May, 2013

(9 years ago)

EP651759B1 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173B1 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A2 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A3 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759A1 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759A4 AKCEA THERAPS Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof.
Jul, 2013

(9 years ago)

EP662003A1 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP662003A4 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion.
Aug, 2013

(9 years ago)

EP662003B1 AKCEA THERAPS Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP672193B1 AKCEA THERAPS Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP672193A4 AKCEA THERAPS Oligonucleotides Having A Conserved G 4? Core Sequence.
Sep, 2013

(9 years ago)

EP672193A1 AKCEA THERAPS Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP716604A4 AKCEA THERAPS Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604B1 AKCEA THERAPS Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604A1 AKCEA THERAPS Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP728139A4 AKCEA THERAPS Gapped Oligonucleotides
Sep, 2014

(8 years ago)

EP728139A1 AKCEA THERAPS Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP728139B1 AKCEA THERAPS Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP734391A1 AKCEA THERAPS Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391A4 AKCEA THERAPS Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391B1 AKCEA THERAPS Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP731807A1 AKCEA THERAPS N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807B1 AKCEA THERAPS N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807A4 AKCEA THERAPS N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP881914B1 AKCEA THERAPS Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP881914A1 AKCEA THERAPS Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP881914A4 AKCEA THERAPS Gapped Oligonucleotides
Feb, 2017

(5 years ago)

EP1218395A4 AKCEA THERAPS Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395A1 AKCEA THERAPS Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395B1 AKCEA THERAPS Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1325019A4 AKCEA THERAPS Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 25 days ago)

EP1325019B1 AKCEA THERAPS Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 25 days ago)

EP1325019A1 AKCEA THERAPS Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 25 days ago)

EP2563920B1 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP2563920A1 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

EP2563920A4 AKCEA THERAPS Modulation Of Transthyretin Expression
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399774 AKCEA THERAPS Modulation of transthyretin expression Apr, 2031

(8 years from now)

US8697860 AKCEA THERAPS Diagnosis and treatment of disease Apr, 2031

(8 years from now)

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.